# FASEB Catalyst Conferences

**Cholangiocarcinoma: Molecular Drivers, Microenvironment, and Precision Medicine**

**Wednesday, April 7, 2021**

Conference Organizer: Alphonse E. Sirica, Ph.D., M.S., Virginia Commonwealth University, Richmond, VA

---

Please note that the schedule is subject to change. All speakers will present live. Recording will not be available after the meeting.

---

<table>
<thead>
<tr>
<th>Time (US Eastern)</th>
<th>Agenda</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:00 pm – 1:10 pm</td>
<td>FASEB Welcome &amp; Organizer Welcome</td>
</tr>
</tbody>
</table>
| 1:10 pm – 2:00 pm | **Keynote Lecture**  
**Cholangiocarcinoma Lessons Learned and Future Predictions: Peering Through a Door Half-Opened**  
Gregory J. Gores, M.D., Mayo Clinic, Rochester, MN |
| 2:00 pm – 3:00 pm | **Session I: Tumor Microenvironment**  
Chair: Alphonse E. Sirica, Ph.D., M.S.,  
**Role of Tumor Reactive Stroma in iCCA Invasiveness**  
Mario Strazzabosco, M.D., Ph.D., Yale University School of Medicine, New Haven, CT  
**Targeting Immunosuppressive Myeloid Cells in Cholangiocarcinoma**  
Sumera Rizvi, M.D., Mayo Clinic, Rochester, MN |
| 2:00 pm – 2:30 pm | **Role of Tumor Reactive Stroma in iCCA Invasiveness**  
Mario Strazzabosco, M.D., Ph.D., Yale University School of Medicine, New Haven, CT |
| 2:30 pm – 3:00 pm | **Targeting Immunosuppressive Myeloid Cells in Cholangiocarcinoma**  
Sumera Rizvi, M.D., Mayo Clinic, Rochester, MN |
| 3:00 pm – 3:30 pm | Break |
| 3:30 pm – 4:30 pm | **Session II: Molecular Drivers and Targets**  
Chair: Alphonse E. Sirica, Ph.D., M.S.,  
**Novel Insights into the Molecular and Immune Subtypes of Cholangiocarcinoma**  
Daniela Sia, Ph.D., Icahn School of Medicine at Mount Sinai, New York, NY  
**Targeting mutant IDH and FGFR fusions in cholangiocarcinoma**  
Nabeel Bardeesy, Ph.D., Massachusetts General Hospital Cancer Center, Harvard University, Boston, MA |
| 3:30 pm – 4:00 pm | **Novel Insights into the Molecular and Immune Subtypes of Cholangiocarcinoma**  
Daniela Sia, Ph.D., Icahn School of Medicine at Mount Sinai, New York, NY |
| 4:00 pm – 4:30 pm | **Targeting mutant IDH and FGFR fusions in cholangiocarcinoma**  
Nabeel Bardeesy, Ph.D., Massachusetts General Hospital Cancer Center, Harvard University, Boston, MA |
<p>| 4:30 pm – 4:35 pm | Organizer’s Closing Remarks |</p>
<table>
<thead>
<tr>
<th>Time</th>
<th>Event Description</th>
</tr>
</thead>
</table>
| 4:35 pm – 5:30 pm | **Virtual Roundtable Discussion: Challenges and Future of Precision Medicine in Cholangiocarcinoma**  
Moderator: Alphonse. E. Sirica, Ph.D., M.S.  
Tim F. Greten, M.D., National Cancer Institute, NIH, Bethesda, MD  
Lewis R. Roberts, M.B., Ch.B., Ph.D., Mayo Clinic, Rochester, MN  \nNilofer Saba Azad, M.D., Johns Hopkins University School of Medicine, Baltimore, MD  
Stacie C. Lindsey, B.A., Founder and CEO, Cholangiocarcinoma Foundation, Salt Lake City, UT |